Hepatitis C Information Central


Discover the latest news about Hepatitis C infection, diagnosis, symptoms and treatments here at Hepatitis-Central.com.

Hep C information

News, Updates and Commentary

Free Newsletter
Hepatitis C Newsletter
We value your privacy. We will not rent your email to anyone.

HEPATITIS NEWS
The top stories compiled from over 5,500 sources, updated every 15 minutes

Pakistan National Hepatitis Control Program
The requested URL /2008/newsUpdates/051508_09.htm was not found on this server.

Schering-Plough Highlights PEGINTRON(TM) And Boceprevir Hepatitis C Data Presentations At Digestive Disease Week (DDW) Annual Meeting
Schering-Plough Corporation (NYSE: SGP), a leader in advancing the science and treatment of chronic hepatitis C virus (HCV) infection, announced that data from several clinical studies with PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin,

Hepatitis C Virus Target Product Profiles 2008 is Now Available
- Research and Markets (http://www.researchandmarkets.com/reports/c91973) has announced the addition of new Decision Resources 'Target Product Profiles 2008: Physician Insights on Key Attributes - Hepatitis C Virus' to their offering. A protease


UPDATES AND COMMENTARY RSS Feed

What You Must Know About Alcoholic Hepatitis
This much-needed synopsis of alcoholic hepatitis reminds us that you don't need to be a heavy drinker to suffer from this condition. Looking over the causes, risk factors and complications of alcoholic hepatitis will motivate anyone with liver concerns to...

15 Tips for Managing Interferon-Ribavirin Side Effects
Finding new ways to manage the side effects of Hepatitis C combination therapy adds to a person’s likelihood of conquering the virus....

New Mexico Offers Free Hepatitis C Hotline
Finally being recognized as the widespread, public health problem that it is, the New Mexico Department of Health has taken a giant step forward to help people with Hepatitis C. By launching a new, toll-free phone number, locals concerned about...



Relationship of the Genomic Complexity of Hepatitis C Virus With Liver Disease Severity and Response to Interferon in Patients With Chronic HCV Genotype 1b Infection

table  2.   Basal Features and Complexity of the HVR1, as Determined by SSCP Analysis, in Patients With Genotype 1b HCV Chronic Infection According to the Response to a Course of Interferon Therapy

Sustained
Response
(n = 12)
Transient
Response
(n = 41)
No
Response
(n = 69)

Age (years) 41.1 ± 13.0 46.4 ± 11.7 48.8 ± 11.4
Sex (M/F) 7/5 22/19 44/25
Source of infection
  Blood transfusion 4 (33.3%) 11 (26.8%) 22 (31.9%)
  I.V. drug abuse 3 (25%)   2 (4.9%) 4 (5.8%)
  Unknown 5 (41.7%) 28 (68.3%) 43 (62.3%)
AST (IU/L) 87.8 ± 60.8 80.0 ± 52.5 109.1 ± 69.3
ALT (IU/L) 190.6 ± 138.1 142.6 ± 85.8 166.5 ± 114.6
HCV-RNA (copies × 103/mL) 25 ± 35* 346 ± 388 415 ± 506
Number of SSCP bands 7.5 ± 3.9 8.3 ± 2.9 8.2 ± 3.6
High complexity of quasispecies 4 (33.3%) 16 (39%)   26 (37.6%)
Low complexity of quasispecies 8 (66.7%) 25 (61%)   43 (62.4%)

NOTE. Quantitative data are expressed as means ± SD. Numbers in parenthesis represent percentages. Complexity of quasispecies was defined as low (8 bands or less) or high (more than 8 bands), according to the median value of the number of bands in the SSCP analysis.
* Significantly different (P = .04) from transient responders and nonresponders by ANOVA.

Return To Article

Copyright © 1999 by the American Association for the Study of Liver Diseases.

  Hep C information

Information at this website is for educational purposes only; statements about products and health conditions
have not been evaluated by the U.S. Food & Drug Administration.

©1994-2008 Hepatitis-Central.com
Updated 16 May 2008